anti mcd103 m290 (Bio X Cell)
Bio X Cell is a verified supplier 
Bio X Cell manufactures this product 
93
Structured Review
Bio X Cell
anti mcd103 m290
Anti Mcd103 M290, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 93/100, based on 24 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd103/InVivoMAb+anti-mouse+CD103/pmc09723959-150-0-2
Average 93 stars, based on 24 article reviews
Anti Mcd103 M290, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 93/100, based on 24 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd103/InVivoMAb+anti-mouse+CD103/pmc09723959-150-0-2
Average 93 stars, based on 24 article reviews
anti mcd103 m290 - by Bioz Stars,
2026-10
93/100 stars
Images
1) Product Images from "Development of 89 Zr-anti-CD103 PET imaging for non-invasive assessment of cancer reactive T cell infiltration"
Article Title: Development of 89 Zr-anti-CD103 PET imaging for non-invasive assessment of cancer reactive T cell infiltration
Journal: Journal for Immunotherapy of Cancer
doi: 10.1136/jitc-2022-004877
Figure Legend Snippet: In vivo anti-mCD103 mAb microPET imaging. (A) Representative coronal 89Zr-anti-M290 and 89Zr-isotype control PET scans, 1, 3 and 6 days post tracer injection in non-tumor bearing C57BL/6 mice. (B) Ex vivo tissue biodistribution of 89Zr-anti-M290 and 89Zr-isotype control in non-tumor bearing C57BL/6 mice, 6 days post-tracer injection (median, n=3). (C) Analysis of ex vivo macroscopic tracer distribution in FFPE tumor tissue slices using autoradiography. (D) immunohistochemical CD103 staining of the small intestine, mesenteric lymph node (left) and colon (right). ALN, axillary lymph node; BLN, brachial lymph node; MLN, mesenteric lymph node.
Techniques Used: In Vivo, Imaging, Control, Injection, Ex Vivo, Autoradiography, Immunohistochemical staining, Staining
Related Articles
other:Article Title: Crystalline silica-induced recruitment and immuno-imbalance of CD4 + tissue resident memory T cells promote silicosis progression Article Snippet: Anti-CD103 treatment: Anti-mouse CD103 (M290, BE0026) and Article Title: Crystalline silica-induced recruitment and immuno-imbalance of CD4 + tissue resident memory T cells promote silicosis progression. Article Snippet: Article Title: Antibody-ALK5 inhibitor conjugates and their uses Article Snippet: Examples of antibodies that bind to T cell surface molecules and believed to be internalizing include OKT6 (anti-CD1; ATCC deposit no. CRL8020), OKT11 (anti-CD2; ATCC deposit no. CRL8027); OKT3 (anti-CD3; ATCC deposit no. CRL8001); OKT4 (anti-CD4; ATCC deposit no. CRL8002); OKT8 (anti-CD8; ATCC deposit no. CRL8014); 7D4 (anti-CD25; ATCC deposit no. CRL1698); OKT9 (anti-CD71; ATCC deposit no. CRL8021); CD28.2 (anti-CD28, BD Biosciences Cat. No. 556620); Control:Article Title: Different tumour-resident memory T-cell subsets regulate responses to anti-PD-1 and anti-CTLA-4 cancer immunotherapies. Article Snippet: A negative isotype control (IgG2a, clone 2A3, Bio-X-Cell BE0089; polyclonal Syrian hamster IgG, Bio-X-Cell BE0087) was included. .. Animals were challenged i.p. with 100μg/mouse anti-CD8 (clone 2.43, Bio-X-Cell BE0061) or anti-CD4 (clone GK1.5, Biolegend 900004676) neutralizing mAb, or received isotype control (IgG2b, clone LTF-2, Bio-X-Cell BE0090; IgG2b, clone RTK4530, Biolegend 400602).We injected 50μg/mouseof anti-CD103 ( Article Title: Visualizing the spatial organization of monocytes, interstitial macrophages, and tissue-specific macrophages in situ. Article Snippet: .. REAGENT or RESOURCE SOURCE IDENTIFIER Antibodies InVivoMab anti-mouse CSF1R BioXcell Cat#BE0213; RRID:AB_2687699 InVivoMab rat IgG2a isotype control, anti-trinitrophenol Bioxcell Cat#BE0089; RRID:AB_1107769 InVivoMab anti-mouse CSF1 BioXcell Cat#BE0204; RRID:AB_10950309 InVivoMab anti-mouse GM-CSF BioXcell Cat#BE0259; RRID: Article Title: Different tumour-resident memory T-cell subsets regulate responses to anti-PD-1 and anti-CTLA-4 cancer immunotherapies Article Snippet: Animals were challenged i.p. with 100 μg/mouse anti-CD8 (clone 2.43, Bio-X-Cell BE0061) or anti-CD4 (clone GK1.5, Biolegend 900004676) neutralizing mAb, or received isotype control (IgG2b, clone LTF-2, Bio-X-Cell BE0090; IgG2b, clone RTK4530, Biolegend 400602). .. We injected 50 μg/mouse of Injection:Article Title: Different tumour-resident memory T-cell subsets regulate responses to anti-PD-1 and anti-CTLA-4 cancer immunotherapies. Article Snippet: A negative isotype control (IgG2a, clone 2A3, Bio-X-Cell BE0089; polyclonal Syrian hamster IgG, Bio-X-Cell BE0087) was included. .. Animals were challenged i.p. with 100μg/mouse anti-CD8 (clone 2.43, Bio-X-Cell BE0061) or anti-CD4 (clone GK1.5, Biolegend 900004676) neutralizing mAb, or received isotype control (IgG2b, clone LTF-2, Bio-X-Cell BE0090; IgG2b, clone RTK4530, Biolegend 400602).We injected 50μg/mouseof anti-CD103 ( Article Title: Fgl2-knockout tumor cells serve as a vaccine inducing long-duration brain-resident memory T cells that reject subsequent intracranial tumor cell challenges. Article Snippet: .. Anti-CD8α (clone 2.43), anti-CD69 (clone CD69.2.2), Article Title: Different tumour-resident memory T-cell subsets regulate responses to anti-PD-1 and anti-CTLA-4 cancer immunotherapies Article Snippet: Animals were challenged i.p. with 100 μg/mouse anti-CD8 (clone 2.43, Bio-X-Cell BE0061) or anti-CD4 (clone GK1.5, Biolegend 900004676) neutralizing mAb, or received isotype control (IgG2b, clone LTF-2, Bio-X-Cell BE0090; IgG2b, clone RTK4530, Biolegend 400602). .. We injected 50 μg/mouse of |